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Cancer is second leading cause of death in the United States. Improving 
cancer care through patient care, research, education and prevention not only 
saves lives, but reduces health care cost as well. Breast cancer is the most 
leading cause of cancer incidence and cancer related death in women of the 
United States. 14-3-3s are a family of conserved proteins ubiquitously expressed 
in all eukaryotic organisms. They form complexes with hundreds of proteins by 
binding to specific phospho-serine/threonine containing motifs. In this way they 
regulate a variety of cellular processes and are involved in many human 
diseases especially cancer to our interest. Our lab and others recently reported 
that the 14-3-3ζ  (zeta) isoform is overexpressed in ~45% breast cancers, which 
predicted poor patient outcome. 14-3-3ζ overexpression confers chemotherapy 
resistance. Additionally, 14-3-3ζ prevents anoikis by suppressing p53 and 
promotes epithelial mesenchymal transition by activating the TGB-β signaling 
pathway, which plays important roles during tumor formation and progression. 
Based on these l hypothesized that 14-3-3ζ  plays an important role in breast 
cancer. 
vii 
To systematically study the role of 14-3-3ζ in breast cancer in vivo, I 
generated a strong 14-3-3ζ hypomorphic mutant mouse model by Gene Trap. 
We found that the homozygous mutant mice are lethal neonatally due to 
respiratory failure. This lethality could be rescued when outbred to CD-1 or 
backcrossed to FVB/N mouse strain.  
Early mammary gland development was not significantly affected in 14-3-
3ζ homozygous mutant mice. When crossed with MMTV driven Polyoma Middle-
T or Neu oncogene transgenic tumor prone mouse, the 14-3-3ζ mutant mice had 
longer tumor latency and reduced lung metastasis compared to their wild type 
counterpart. The tumor samples from the 14-3-3ζ mutant mice displayed 
reduced proliferation, increased apoptosis and reduced angiogenesis. Multiple 
genes were differentially expressed in the 14-3-3ζ knockout tumors. MiR-126 
was an important microRNA mediating both the lethality and tumorigenesis 
inhibition phenotype.  
In addition, 14-3-3ζ knockout mice are smaller than their litter mates. This 
growth retardation was accompanied with reduced growth hormone but 
increased IGF-1 level in the circulation. The knockout mice had a defect in 
glucose homeostasis. They have lower blood glucose and tolerate glucose 
better than their wild type counterparts due to reduced glucose uptake. The 
aberrant glucose homeostasis was accompanied by reduced Hif1-α and Igf1r 
expression.  
viii 
The 14-3-3ζ knockout mice had other phenotypes that need to be further 
characterized. This mouse strain provided new resource to study 14-3-3ζ 
function in vivo and potentially could benefit patients that have aberrant 
expression of 14-3-3ζ.  
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Chapter 1 
Introduction 
1.1 Cancer 
1.1a Definition 
 Cancer, also termed as malignant neoplasm, is defined as a group of 
more than 100 diseases in which cells in a part of the body display uncontrolled 
growth, invade and destroy adjacent tissues, and very often spread to other 
locations of the body through lymphatic system or blood stream known as 
metastasis. It is different from benign tumor in which the cells do not proliferate 
without control, invade locally or metastasize to distant organs. Cancer, if left 
untreated, can cause serious illness and even death. 
1.1b Cause 
 Cancer can be an inheritable genetic disease, like BRCA1/2 gene 
mutation in breast cancer, APC gene deletion in colon cancer and PTEN loss in 
many types of cancers. However, the majority of cancers are caused by 
environmental factors like exposure to alcohol, smoking, radiation, infection, diet 
and exercise etc. The most significant risk factor is aging.  
1.1c Statistics 
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 Cancer is the second leading cause of death in the states. More than 11 
million people are suffering from cancer nowadays according to National Cancer 
Institute's Surveillance Epidemiology and End Results (SEER) database. It is 
estimated that about 40% people will develop cancer in their lifetime and more 
than 20% will die from it. The cost of cancer is more than 228 billion dollars 
annually. Improving cancer care through patient care, research, prevention and 
education is critical not only for eliminating cancer mediated suffering and death, 
but also for helping to keep the nation in good financial figure. 
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1.2 Breast cancer 
1.2a Definition 
 According to the definition of National Cancer Institute, breast cancer is 
the type of neoplasm that forms in tissues of the breast, usually the ducts (tubes 
that carry milk to the nipple) and lobules (glands that make milk). It occurs in 
both men and women, although male breast cancer is rare. Like most cancers, 
breast cancer is influenced by many risk factors, like heritable genetic mutations, 
exposure to toxic chemicals, diet and living styles etc. 
1.2b Statistics 
 Breast cancer is the most leading cause of cancer incidence and cancer 
related death in women of the United States. It is estimated that 230,480 women 
will develop breast cancer this year, and 39,520 will die from it. About one out of 
eight women will develop breast cancer in their life time. Thanks to the recent 
breast cancer care improvement, breast cancer is highly treatable if detected 
early with combination of surgery, chemotherapy, radiation therapy and hormone 
therapy. The five-year survival rate of breast cancer, when diagnosed at 
localized primary site, is over 98%. However, this rate drops to 23.4% if 
diagnosed as metastatic disease (data obtained from American Society of 
Cancer online). 
1.2c Research models 
4 
Breast cancer development has been modeled as a multi-step process starting 
from normal mammary epithelium to ductal hyperplasia, atypical ductal 
hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive carcinoma, ending 
with tumors capable of metastasizing to distant organs. These steps are defined 
by a series of morphological changes based on epidemiological and histological 
observations (Figure 1) (1, 2). This model has been wildly used to understand 
how breast cancer initiate and progress into killing disease. 
 However, breast cancer is not a single disease but a collection of 
heterogeneous diseases that have distinct histopathological features, genetic 
variability and diverse prognostic outcomes. It is realized that no individual 
model can completely recapitulate this complex disease (3).  
 Currently breast cancer cell lines, xenografts and genetically engineered 
mouse models are widely used in the field of breast cancer research to 
understand breast cancer from different angles (3).  
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Figure. 1 Schematic of breast cancer tumorigenesis and 
progression 
Polyak K. et. al. 2001 
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1.3 14-3-3 family proteins 
1.3a General property 
 14-3-3s are a 28-33kd conserved family proteins ubiquitously expressed 
in all eukaryotic organisms (4). They were first found in 1967 as abundant 
proteins in bovine brain. The name of 14-3-3 was determined by their fraction 
number on a 2D DEAE-cellulose chromatography and the migration position in 
subsequent starch gel electrophoresis (5). They comprise about 1% soluble 
protein in the brain (6).  
 There are 7 highly homologous isoforms in mammals, namely β, γ, ε, σ, ζ, 
τ and η (7). 14-3-3s are highly conserved proteins. There are 2 isoforms in yeast 
and drosophila, and there are 15 isoforms in plants. The Saccharomyces 
cerevisiae isoform BMH1 share ~70% amino acid sequence homology with 
mammalian 14-3-3ε isoform. This similarity strongly suggest high degree of 
functional conservation (8). 
1.3b Function discovery 
 It was not until 20 years after the initial discovery, was the first function of 
14-3-3 discovered as an activator of tryptophan and tyrosine hydroxylases which 
is necessary for dopamine synthesis and other neurotransmitters (9).  
 14-3-3 binds to a variety of target proteins many of which are involved in 
cancer including receptors like IGF1R(10, 11), kinases like Raf-1 (12-17) and 
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Bcr (18), docking molecules like insulin receptor substrate I (IRS-1) (19) and 
p130Cas (20), phosphotase like Cdc25 (21), death regulator like Bad (22), and 
oncogene products like Polyoma-virus middle tumor antigen (PyMT) (23) and 
Bcr-Abl (18), which indicated that 14-3-3 could be potential oncogene (24). 
These findings of 14-3-3s interaction with different targets in biochemical and 
genetic screenings reflected the physiological importance of 14-3-3s in diverse 
cellular pathways (8). 
 As 14-3-3 lack endogenous enzymatic activity, it was thought to be 
allosteric cofactor or molecular chaperone to affect the target proteins enzymatic 
activity, subcellular localization, protein stability, interaction with other molecules 
and post-translational modification (4).  
1.3c Target interaction 
 Although 14-3-3 can bind to the target proteins independent of 
phosphorylation, 14-3-3 binds to their ligands mainly in a phosphorylation 
depedent manner. 14-3-3 is the first protein family that binds to specific 
phospho-serine/threonine containing motif (25, 26). By screening oriented 
peptide library, two consensus motifs were found to interact with 14-3-3, 
RSXpSXP (mode 1) and RXXXpSXP (mode 2), where pS represents 
phosphoserine (27, 28).  
1.3d Structure basis 
8 
 14-3-3s are highly homologous in their amino acid sequence (8). It is 
predicted that the each isoform may have specific functions. However, the 
structure studies did not support this hypothesis. 14-3-3 isoforms are highly 
similar in their dimeric structure (27-30). Crystal structure indicated that 14-3-3 
forms heterodimer or homodimer in cells. The 14-3-3ζ dimer is in a flattened 
horseshoe shape. Each monomer contains 9 α-helices that are organized in an 
anti-parallel manner. The first 4 helices are necessary to form the dimer. The 
helices-3, 5, 7, 9 composed a conserved amphipathic binding groove(29) . This 
structure is conserved in all 14-3-3 isoforms (28). (Figure 2, 3) 
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Figure 2. Crystal structure of 14-3-3ζ dimer. The red part indicates 14-3-3ζ 
structure. The blue part indicates the 14-3-3 binding motif in integrin beta2 
variant chain. The yellow part indicates the phosphorylated threonine site. 
Diagram generated by PyMOL software using PDB ID# 2V7D 
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Figure 3. 14-3-3s share high similarity in their amino acid sequence and crystal 
structure. Ten 14-3-3 proteins from different species were aligned with 
CLUSTAL algorithm. α-helices are indicated above the sequence using black 
rectangles. Nucleus exportation signal sequence was colored in yellow below 
the sequence. 5 blocks with highest sequence homology are shaded in purple 
and the residues responsible for direct target binding are shaded in red.  
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1.3e Regulation of 14-3-3  
The isoform specific functions of 14-3-3s could be achieved by at least 3 ways, 
strict regulation of cell type specific isoform expression, post-translational 
modification and regulation of the availability (8, 24). The brain constitutively 
expresses most 14-3-3 isoforms, whereas the other tissues express mainly one 
or another isoform (31-33). 14-3-3 can be phosphorylated at S58 (34), S184 (35) 
and T232 (36). These phosphorylatioin either inhibited the dimerization of 14-3-3 
monomers or inhibited 14-3-3 binding to the target proteins, which inhibited 14-
3-3 function. The cell can also express fluctuated level of 14-3-3 ligands, thus 
competitively regulating the availability of 14-3-3 to other target proteins.(37-39) 
1.3f Specificity function of 14-3-3 isoforms 
 Recent studies have revealed that each 14-3-3 isoform preferentially 
binds to their target proteins and is involved in different biological processes and 
human diseases. 14-3-3σ has been known to stabilize p53 and hence 
suppresses tumor growth (40-42) and is frequently lost in cancer (43-46). 14-3-
3σ also binds to Par3 and regulate cell polarity (47). 14-3-3ε binds to TGFβRI 
thereby enhancing TGF-β signaling (48). 14-3-3ε can also bind to PolyA 
polymerase and regulates its cellular localization (49). Loss of 14-3-3ε in mouse 
models results in embryonic lethality and haplo-insufficiency leading to neuronal 
development defects which mimics the human Miller-Dieker Syndrome (MDS) 
(50). 14-3-3γ binds to PKC and regulates PDGF signaling in vascular smooth 
muscle cells (51). Mice with targeted deletion of 14-3-3γ did not show any 
12 
obvious phenotype (52). 14-3-3τ regulates E2F stability and is required for 
autophagy (53). 14-3-3τ knockout mice were embryonic lethal. 14-3-3τ 
heterozygous mice were haploinsufficient and were sensitive to myocardial 
infarction (54).  
 So although 14-3-3 isoforms are highly homologous and structurally 
similar to each other, they have different function both in vitro and in vivo. 
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1.4 14-3-3ζ 
1.4a 14-3-3ζ in human diseases 
Among all the 14-3-3 isoforms, the 14-3-3ζ (zeta) has been demonstrated to be 
involved in several human diseases, like Creulzfeldt-Jakob Disease (CJD) (55), 
Alzheimer Disease (33, 56), progressive multifocal leukoencephalopathy (PML) 
(57), atherosclerosis (58), Huntington disease (59) and especially multiple 
cancer types including lung (60, 61), breast (62, 63), ovarian (64), head and 
neck (65), oral cancers (66) and lymphomas (67). These data support the idea 
that 14-3-3ζ is critical in human diseases. However, how exactly 14-3-3ζ 
functions in these diseases remain to be explored. Studying the role of 14-3-3ζ  
could provide new opportunities to develop better therapy and potentially benefit 
the patients. It is urgent to develop animal model in which 14-3-3ζ  expression 
could be manipulated to study the role of 14-3-3ζ  in vivo. Unfortunately no such 
animal models have been reported and available to the field so far.  
1.4b 14-3-3ζ in breast cancer 
14-3-3ζ isoform is. It is located on chromosome 8q22 which is frequently 
amplified in breast cancer (68). We and others have shown that 14-3-3ζ is 
overexpressed in ~45% breast cancer patients mainly due to amplification which 
predicts poor clinic outcome (62). Overexpression of 14-3-3ζ resulted in 
chemotherapy resistance in breast cancers (68). 14-3-3ζ activates Akt, 
suppresses p53 and hence rendering the cells resistant to apoptosis (69). 14-3-
14 
3ζ can bind to TGFβRI, stabilize it and promotes epithelial-to-mesenchymal 
transition (EMT). It also cooperates with ErbB2 to promote early stage breast 
lesion to invasive breast cancer (63).  All these data suggest that 14-3-3ζ plays 
important role in breast cancer. 14-3-3ζ can be a potential therapeutic target in 
breast cancer and other cancer types (70) 
15 
1.5 MicroRNA-126 
MicroRNAs are a class of ~22 nucleotide noncoding RNAs that regulate gene 
expression by either promoting mRNA degradation or repressing protein 
translation (71). Hundreds of microRNAs have been identified in human and 
other eukaryotes. Many of them are transcribed from introns of protein coding 
genes or intergenic sequences. MicroRNAs are initially transcribed as large pri-
microRNAs in the nuclear. After cleavage by Drosha complex, pre-microRNAs 
will be generated and translocated into the cytoplasm. Then the ribonuclease 
Dicer and its cofactors will process the precursors into 19-25nt microRNA 
duplexes. The microRNA heteroduplex will incorporate into RNA-induced 
silencing complex (RISC) where the microRNAs could target specific mRNA 
through complementary binding to the 3’-UTR region. In animals the 5’ proximal 
“seeding” sequences (nucleotide 2 to 8) appear to be the major determinant of 
paring specificity (72, 73). More than one-third human genes could be regulated 
by microRNAs (74). The opposite strand known as star (*) strand is generally 
degraded. In this way MicroRNAs regulate a wide variety of biological processes 
(75).   
MicroRNA-126is located in the intron 7 of EGFL7 gene (76). It will transcribe into 
2 mature miRNAs, miR-126 and miR126*. MiR-126 expression was detected in 
all tissues with the highest in heart and lung. MiR-126 is an endothelial specific 
microRNA that regulates vascular integrity and angiogenesis (76-78).Targeted 
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deletion of miR-126 resulted in lethality and lung deflation along with vascular 
leakage, edema and hemorrhaging (76).  
MiR-126 has been reported to involve in several human diseases such as type II 
diabetes (79), malaria (80), coronary artery disease (81) cystic fibrosis (82) and 
cancer (83-86). Its role in cancer has remained controversial and need to be 
elucidated in the future (87).  
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Rationale, Purpose and Significance 
According to the previous introduction, I hypothesized that 14-3-3ζ plays 
important role in breast cancer formation and progression. Better understanding 
the role of 14-3-3ζ in breast cancer could help us understand this disease better. 
I would like to test this hypothesis in a genetically engineered mouse (GEM) 
model which could collectively demonstrate breast cancer biology in vivo.  
Our lab previously found that knocking down 14-3-3ζ using siRNAs sensitized 
breast cancer cells to stress induced apoptosis without affecting its most 
homologous isoform, 14-3-3β (62), which suggested that 14-3-3ζ had specific 
important functions that could not be compensated by other 14-3-3 isoforms.  
14-3-3ζ gene is located on mouse genome chromosome 15 without any other 
known genes or non-coding RNAs located inside or close to that region, which 
made the knockout of 14-3-3ζ feasible. Any phenotype observed in the 14-3-3ζ 
gene knockout mouse is likely to be specific to loss of 14-3-3ζ alone. 
So I decided to generate a 14-3-3ζ knockout mouse strain, in which I could 
study the function of 14-3-3ζ in vivo. Meanwhile I could initiate to test whether 
14-3-3ζ could be a cancer therapeutic target. This study could potentially benefit 
a big proportion of patients who had aberrant regulation of 14-3-3ζ. 
18 
Chapter 2 Material and Methods 
2.1 14-3-3ζ knockout Mice Generation and Maintenance 
 ES cell line RRR334 was obtained from Mutant Mouse Regional 
Resource Center (MMRRC). RT-PCR was performed to confirm that the cell line 
inactivates 14-3-3ζ. The primer sequence for the exogenous was forward: 5’-
TGCTGAGAAAAAGCAGCAGA and reverse: 5’- 
GACAGTATCGGCCTCAGGAAGATCG. The primer sequence for endogenous 
14-3-3ζ ctrl PCR was forward: 5’- TGCTGAGAAAAAGCAGCAGA and reverse: 
5’- TTGTCATCACCAGCAGCAAC. Genetic Engineered Mouse Facility at MD 
Anderson Cancer Center injected the cells into C57Bl/6 albino blastocysts. The 
chimera mice were mated with C57Bl/6 albino mice to test germline transmission 
and get 14-3-3ζ knockout founder mice. The primer sequences for PCR 
genotyping were forward: 5’- CAACCATGTTGGGATAGAGG homologous to 14-
3-3ζ intron 3, reverse: 5’- CCAAATAAGCCTTCCCTTCC homologous to intron 3 
and 5’- AAGGGTCTTTGAGCACCAGA homologous to the gene trap vector. The 
PCR will generate a 954bp fragment from the wild type allele and a 544bp 
fragment from the mutant allele. Mice were backcrossed into C57Bl/6, FVB/N 
congenic background or outbred to CD-1 genetic background respectively and 
maintained since then. The C57Bl/6J and FVB/NJ mouse breeders were 
purchased from the Jackson Laboratory, Bar Harbor, Maine. The CD-1 breeders 
were purchased from Charles Rivers, Wilmington, MA.  
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2.2 Mammary Gland Whole Mounts 
The number 4 mammary glands on the left side of the mice were spread onto 
microscopic slides, fixed in Carnoy's fixative overnight, hydrated and stained 
with carmine alum stain (Sigma, St. Louis, Mo) overnight, and were then 
dehydrated through sequential ethanol, treated with xylene to remove fat, and 
mounted with Secure Mount (Fisher Scientific, Pittsburgh, PA) and cover slips. 
Mammary gland tissue samples were collected during all phases of the estrous 
cycle. The samples were imaged using Zeiss Discovery V20 dissection 
microscope and axiom imaging software that came with the microscope.  
 2.3 Tissue Collection and Histological Analysis 
The mouse embryos were collected by C-section at 18.5dpc. The lung tissues 
were collected after euthanasia following IACUC.  
Mammary tumor formation was monitored by palpation twice a week. Upon 
formation of a palpable tumor, the mice were observed for 3-4 weeks for tumor 
progression. When the tumor diameter reached 15mm, the mammary tumors 
and lungs were harvested. Excised lungs were examined for grossly detectable 
lesions.  
Tissues were fixed in 10% neutral buffered formalin for 12-18 h. The samples 
were stored in 70% ethanol, and then embedded in paraffin. Paraffin sections of 
5µm were stained with hematoxylin and eosin. Mammary tumor histology and 
lung metastasis were independently evaluated by two pathologists (Y.X and 
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H.W). Immunohistochemistry (IHC) was performed as previously described (63). 
Antibodies used are Ki67 (DAKO, Carpinteria, CA M7249), Tunel (Roche, 
Indianapolis, IN), CD34 (eBioscience, San Diego, CA 14-0341), 14-3-3ζ (C-16, 
Santa Cruz, Santa Cruz, CA sc-1019).SP-A (Santa Cruz sc-13977), AQP5 
(Calbiochem, Germany 178615). For IHC analysis and quantification, 10 fields 
were randomly chosen at 200X magnification. The total number of cells and 
positive cells were counted and the average percentage of positive cells was 
determined. 
2.4 Immunoblotting  
Tissues and mammary tumors were collected from mice. Protein extracts were 
made by homogenizing samples in tissue lysis PBSTDS buffer [10 mmol/L 
sodium phosphate (pH 7.3), 154 mmol/L NaCl, 5% sodium deoxycholate, 1% 
SDS] using a tissue grinder, followed by centrifugation to remove particulate 
matter and lipids. Immunoblotting was performed as previously described (63). 
Antibodies used are anti-HA high affinity (clone 3F10, Roche 11867423001), 14-
3-3ζ (C-16, Santa Cruz sc-1019), Neu (C-18, Santa Cruz sc-284), Erk (Cell 
Signaling 4695), pErk (T202/Y204, Cell Signaling 4370), Mek1 (Cell Signaling 
9126), pMek1 (S221, Cell Signal 2338), Akt (Cell signaling 9272), pAkt (S473, 
Cell signaling 3787), p53 (DO-1, Santa Cruz sc-126), Bax (B-9, Santa Cruz sc-
7480), VEGF (A-20, Santa Cruz sc-152), PyMT(Novus Biologicals NB100-2749), 
β-actin (Sigma A5441),  α-tubulin (Sigma T5168), HIF1-α (Novus Biologicals 
NB100-105) and IGF1R-β (Cell Signaling 3027) 
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 2.5 Quantitative RT-PCR for microRNA quantification 
RNA of the tissue samples was retrieved using Trizol (Invitrogen, Carlsbad, CA) 
following the standard protocol. Reverse transcription was performed using 
Taqman MicroRNA Reverse Transcription kit ( Applied Biosystems 4366569) 
and real time PCR was performed using Taqman Universal PCR Master Kit 
(Applied Biosystems 4324018) and iQ SyBR Green Supermix (Bio-Rad 170-
8882). The specific primers and probe for miR-126 RT-PCR was purchased from 
Applied Biosystems, 4427975-002228. The real time PCR was done on Bio-Rad 
iCycler Real Time PCR machine. The primer sequences for CD31 are forward: 
5’- CTGGTGCTCTATGCAAGCCT and reverse: 5’- 
AGTTGCTGCCCATTCATCAC. The primer sequences for 18S ribosome protein 
are forward: 5’- AACCCGTTGAACCCCATT and reverse: 5’- 
CCATCCAATCGGTAGTAGCG. 
2.6 Transwell migration assay 
3x104 mouse endothelial cells resuspended in 500ul serum free medium were 
seeded in the top chamber of the 24-well 8-um pore transwell plates. 600ul 10% 
FBS containing medium was used as chemo-attractant in the bottom chamber. 
The plates were incubated at 37C for 4 hours. The cells were fixed in 10% 
neutral buffered formalin for 1 hour and stained with 0.5% crystal violet for 1 
hour. The plates were flushed under tap water to remove excessive dye. The 
cells that did not migrate were removed by cotton tips. Images were taken with 
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Zeiss Discovery V20 microscope with equipped software. Quantification of the 
migrated cells was performed using Adobe Photoshop and ImageJ software.  
2.7 Tube formation assay 
Matrigel (BD, Franklin Lakes, NJ 356231) was thawed at 4C overnight before 
assay. 500ul matrigel was added into each well of the 24-well plate. The plates 
were incubated at 37C 30 minutes to 1 hour to form gel. 3x105 cells 
resuspended in 10% FBS containing DMEM/F-12 medium were plated above 
the matrigel and incubated for 6 hours at 37C. Tube formation of the endothelial 
cells was imaged with Olympus inverted fluorescence microscope and quantified 
using ImageJ software.  
2.8 Assessment of Proliferation, Apoptosis, and Angiogenesis 
To assess proliferation rate or apoptosis, 1000 tumor cells were counted for the 
percentage of Ki67 or TUNEL positive-staining cells by investigators blinded to 
the identity of the mice. Angiogenesis was evaluated by CD34 IHC staining and 
by counting blood vessels in three areas of the section at 200X magnification. 
The blood vessel index was expressed as the mean number of vessels in the 
three areas. 
2.9 Growth Hormone Measurement 
Blood samples were extracted through tail vein from 4 week old mice of both 
sexes. Blood samples were placed on ice 2h to allow aggregation.  Centrifuge 
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the samples at 1500g for 10 minutes. Collect the top clear part of serum.  Mouse 
circulating growth hormone was measured using ELISA kit (Diagnostic Systems 
Laboratories, Webster, TX DSL-10-72100) following the product instruction. 
2.10 Circulating IGF-1 Measurement 
Mouse circulating IGF-1 was measured using RIA kit (Diagnostic Systems 
Laboratories DSL-2900) following the product manual.  
2.11 Blood Glucose Measurement 
A drop of blood was retrieved from a tail snip. Blood glucose level was 
measured using Roche AccuChek Aviva blood glucose test system. Blood 
drawing was performed ad libitum. 
2.12 Glucose tolerance assay 
Age matched mice with different genotypes were fasted for 16 hours. Roche 
AccuChek Aviva blood glucose test system was used to measure blood glucose 
level of the mice. Basal blood glucose was measured using the blood retrieved 
from the tail snips and was set as time point of 0 minute. 3g/kg weigh of glucose 
was injected intraperitoneally. Blood glucose was measured at the time points of 
15, 30, 60 and 120minutes after injection. 
2.13 Glucose uptake measurement 
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 Mice were injected (i.v.) 100 ul of 2-NBDG (50uM) and sacraficed 30 minutes 
later. Their livers and brains were collected and imaged by Maestro Imaging 
System (CRi Inc.) to measure 2-NBDG uptake in vivo. Fluorescence intensity 
was measured using ImageJ software. 
2.14 Statistical Analyses 
Analysis of mammary tumor latency was performed using the Kaplan-Meier 
method. Differences in survival were determined using log-rank test. Other 
statistical differences were assessed with Student’s t-test or one-way ANOVA. A 
P-value of <0.05 was considered statistically significant.  
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Chapter 3 Results and Discussion 
3.1 Generation of 14-3-3ζ knockout mouse 
3.1a Generation of 14-3-3ζ mutant mouse strain 
To systematically study the role of 14-3-3ζ in vivo, I generated a 14-3-3ζ 
knockout mouse strain by gene trap. The cell line RRR334, in which 14-3-3ζ 
was inactivated according to the 5’RACE data from Baygenomics database, was 
obtained from the Mutant Mouse Regional Resource Center (MMRRC). We 
confirmed silencing of 14-3-3ζ in the cell line by RT-PCR using a forward primer 
homologous to exon 3 and a reverse primer homologous to β-geo cassette in 
gene trap vector, pGT0Lxf, followed by sequencing the PCR product (Figure 4). 
By designing multiple forward primers homologous to intron 3 and PCR 
amplification along with a reverse primer homologous to gene trap vector, I 
identified the exact integration site of the gene trap vector in 14-3-3ζ gene. The 
first 152 base pairs (bp) of the gene trap vector were lost during integration. The 
integration site of the gene trap vector was located about 3351bp downstream of 
exon 3 as determined by PCR and sequencing the PCR product (Figure 5). 
Southern blot was also designed and performed to confirm the genomic 
integration. PCR genotyping primers were designed based on the integration 
site (Figure 6).  The ES cells were injected into C57Bl/6 albino mouse 
blastocysts by the Genetic Engineered Mouse Facility (GEMF) at MD. Anderson 
Cancer Center.  Chimera mice with high ES cell contribution based on their fur 
color were mated with C57Bl/6 albino mice to determine germ line transmission 
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and obtain 14-3-3ζ knockout founder mice. Founder 14-3-3ζ heterozygous (+/-) 
male with (+/-) female mice were mated to generate 14-3-3ζ homozygous (-/-) 
mutant mice. 
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Figure 4. RT-PCR confirmation that the ES cell line RRR334 had 14-3-
3ζ inactivated. Schematic view of that the gene trap vector integrated into the 
intron 3 of 14-3-3ζ gene. Ywhaz is the HUGO Gene Nomenclature Committee 
approved gene symbol for 14-3-3ζ. The line indicates the introns for 14-3-3ζ 
gene, whereas the rectangles indicate the exons. The solid parts indicate the 
coding region for 14-3-3ζ protein. The gene trap vector pGT0Lxf was integrated 
~3.3kb downstream of exon 3. SA is short for the splice acceptor sequence of 
mouse En2 exon 2. β-Geo/pA indicates the fusion of β-galactosidase and 
neomycin transferase followed by SV40 polyadenylation signal. The arrows 
indicate the primers for RT-PCR. The scale bar is for 1kb length of DNA 
sequence. The endogenous 14-3-3ζ is expressed both in wild type ES cell 
control, TC1 and the mutant cell line RRR334. The exogenous mutant allele only 
exists in the RRR334 cell line. 
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Figure 5. Determination of the gene trap vector integration site in 14-3-3ζ 
genome using PCR. The integration of the gene trap vector into 14-3-3ζ 
gene is described earlier. The arrows indicate the primer for PCR. The 
numbers on each lane of the gel indicate the primer position in the 14-3-
3ζ gene. “N” is for negative control and “M” is for marker. The 1636bp and 
506bp maker sizes are shown. 
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Figure 6. Genotyping of 14-3-3ζ mutant mouse. A. schematic view of the 
integration of the gene trap vector into 14-3-3ζ gene as described earlier. 
Arrow heads indicate the primers for genotyping. B. Representative data of 
PCR genotyping of 14-3-3ζ wild type (+/+), heterozygous (+/-) and 
homozygous mutant (-/-) mouse. “M” is for DNA marker. 1kb and 0.5kb 
DNA fragments were indicated as shown. Wild type allele generated a 
954bp band and the mutant allele generated a 544bp PCR product. 
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3.1b This mouse strain is a strong hypomorphic mutant model for 14-3-3ζ 
14-3-3ζ expression was significantly inhibited in multiple tissue types from the 
knockout mice, especially in mammary gland to our interest (Figure 7). As the 
exon 3 which encodes the first 98 amino acid was expected to be expressed as 
a fusion protein followed by the β-geo cassette, I tested whether the N-terminal 
part of 14-3-3ζ protein had any function. We transfected the HA-tagged N-
terminal 145 amino acids of 14-3-3ζ which encodes a shortened 14-3-3ζ form 
lacking the C-terminal target binding groove structure (29, 30) and should be 
similar with the N-terminal 98aa 14-3-3ζ fragment in term of structure, into MCF7 
cells. I found that the protein was barely detectable by western blot using HA 
antibody. Only when the cells were treated with the proteasome inhibitor MG132 
could we detect the expression of the HA tagged protein. I could not detect the 
14-3-3ζ/β-geo fusion protein in mouse tissues by western blot using either 14-3-
3ζ or β-gal antibody. There was no difference in proliferation as determined by 
MTT assay. The activation of Ras/Raf/Erk and PI3K/Akt signaling, as indicated 
by phosphorylated Mek1 and Akt, which could be activated by overexpression of 
14-3-3ζ (12, 88), were not affected (Figure 8). It is also reported that C-terminal 
deleted 14-3-3 could not bind to hTERT and promote its nuclear translocation 
(89). Based on these, I conclude that the N-terminal part of 14-3-3ζ is not 
functional probably due to its rapid degradation. Considering all these data, this 
mouse strain is a strong hypomorphic mutant model in which we can study the 
role of 14-3-3ζ in vivo.  
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Figure 7. 14-3-3ζ is significantly downregulated in homozygous mutant 
mouse mammary gland. A. Western blot to detect 14-3-3ζ expression in 
wild type (+/+), heterozygous mutant (+/-) and homozygous mutant (-/-) 
mouse mammary gland. β-actin was used as loading control. B. 
Quantification of 14-3-3ζ expression in different genotyping mice tissues 
from 3 independent experiments. 
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Figure 8. 14-3-3ζ N-terminal fragment is non-functional. A. 14-3-3ζ N-terminal 
fragment was not stable. Western blot of lysate from MCF7 transfected with 
vector control (Vc) and 2 HA-tagged delta-C-terminal fragment of 14-3-3ζ  
transfected cell lines (dC1 and dC12) treated with DMSO or 50nM MG132 for 
4 hours. Endogenous 14-3-3ζ was detected using 14-3-3ζ antibody while the 
exogenous 14-3-3ζ fragment was detected using HA antibody. β-actin was 
used as loading control. B. 14-3-3ζ N-terminal fragment did not affect 
proliferation in MCF-7 cells suggested by MTT assay. OD was measure at 
570nm and normalized to 650nm. C. 14-3-3ζ N-terminal fragment did not 
activate Mek1 and Akt indicated by their phosphorylation status. β-actin was 
used as loading control  
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3.1c Discussion 
The strategy I used to knockout 14-3-3ζ was gene trap. Gene trap is a high-
throughput method to inactivate specific gene expression by introducing 
insertional mutations genome wide. In addition to the traditional loss of function 
mutant alleles introduced, recently developed gene trap vector also allowed a 
variety of post-insertional modification strategies for the generation of other 
experimental alleles. It is a very valuable resource for the research community to 
study specific gene function in vivo.  For more details about how gene trap 
works, one can go to the International Gene Trap Consortium at www.igtc.org for 
more information. 
Despite of all the advantages gene trap provides, it has intrinsic limitation and 
pitfalls as well. I had two concerns. First, gene trap utilized strong splicing 
acceptor site to make alternative RNA splicing product in competition to the 
endogenous gene. It is highly possible that the endogenous gene was still 
expressed at certain extent. The dosage of the leakage may be critical for any 
phenotype I would observe. Secondly, gene trap of the host gene will result in a 
fused mRNA product composed of the exons in front of the gene trap insertion 
site and the β-geo cassette. If the exons encode protein sequences, it is 
necessary to confirm that part of the protein is not functional. Any retain of 
function, gain of function, dominant negative would interfere the interpretation of 
the data we generate from the mouse.  
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Here I experimentally showed that endogenous 14-3-3ζ expression is 
significantly downregulated in the knockout mouse tissues and the N-terminal 
part of 14-3-3ζ is not functional. Only ~5% 14-3-3ζ was expressed compared to 
the wild type mouse tissues. The remaining 14-3-3ζ protein probably cannot play 
full function as that in the wild type mouse tissues. With these data in hand, I can 
be confident to move on to test the phenotype mediated by loss of 14-3-3ζ. 
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3.2 14-3-3ζ knockout mice are lethal neonatally 
3.2a 14-3-3ζ mutant mice are lethal neonatally in C57Bl/6 genetic 
background 
An interesting phenotype was observed after mating the founder mice and that is 
only about 5% of the offspring generated from mating heterozygous male and 
female founders were 14-3-3ζ homozygous mutant mice as determined by PCR 
genotyping 10 days after birth (table 1).  This indicates that 14-3-3ζ knockout 
mice may be lethal during embryo development or quickly after birth.   
As about 5% homozygous mice survived, the genetic background is likely to play 
important role mediating the lethality phenotype. To test this, I backcrossed the 
mutant to strain into congenic C57Bl/6 genetic background determined by 
genome scan using a panel of simple sequence length polymorphisms (SSLP) 
(microsatellites) markers. No homozygous mutant pups were found at the time 
of genotyping 10 days after birth (table 1), which confirmed the lethality 
phenotype we observed in B6/129P2 hybrid genetic background. The lethality is 
even more severe in this genetic background. To determine the time point when 
the 14-3-3ζ knockout embryos die, we dissected the embryos at 18.5dpc. We 
observed that the ratio of the knockout embryos matched the Mendellian 
Inheritance Law, which indicated that the 14-3-3ζ knockout embryos were alive 
at this time point (table 1). In contrast to that the wild type and heterozygous 
embryos that started to breathe, became red and survived after dissection, the 
knockout embryos got pale and died quickly after dissection after several 
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attempts to breathe. Similar phenomenon was observed in new born mice, 
which suggested that the 14-3-3ζ knockout mice are lethal neonatally in C57Bl/6 
genetic background. 
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Strain/genotype +/+ +/- -/- P-value 
B6/129P2 F2 22 39 3 0.0052** 
B6 congenic 58 72 0 <0.0001*** 
B6-18.5dpc 16 32 15 0.9879 
CD-1 36 73 38 0.9849 
 
Table 1. 14-3-3ζ knockout mouse are lethal neonatally in C57Bl/6 genetic 
background and are viable in CD-1 background. Genotyping of pups generated 
from mating heterozygous breeders was performed 10 days after birth. 
Genotyping of the embryos were dissected at 18.5dpc (days postcoitus). B6 
indicates the C57Bl/6 strain. 129P2 was previously name as 129/OlaHsd in 
which background the ES cells were originally generated.  
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3.2b 14-3-3ζ mutant pups die due to respiratory failure 
All the 14-3-3ζ knockout embryos die within 0.5 hour after dissection indicating 
that they may die from breathing distress (90). To test this, we dissected the 
lungs of the embryos. In contrast to the wild type lungs which floated in water, 
the knockout lungs sank, suggesting no air got into the lungs. The same 
phenomenon was also observed in new born knockout pups. So it is concluded 
that the 14-3-3ζ knockout mice are lethal neonatally due to respiratory failure. 
H&E staining of the lung section indicated that the knockout mice had defects in 
lung development and was stuck at the pseudoglandular stage. The lungs 
lacked saccular structure and had increased mesenchymal compartment and 
thickened saccular septae (Figure 9). To better understand the pathology in the 
knockout lungs, we performed immunohistochemistry staining on the lung 
sections. There was no difference in proliferation as determined by Ki67, type I 
and type II pneumocyte differentiation determined by pulmonary surfactant-
associated protein A (SP-A) and Aquaporin isoform 5 (AQP5) staining(Figure 
10). Interestingly, we found that the blood vessels in the knockout lungs were 
not integrated. Around the vessels, there were aggregations of leukocytes. 
Meanwhile there were increased blood cells in the knockout lung section 
compared to the wild type counterparts. These data suggest that defects in 
angiogenesis play an important role mediating the breathing distress in the 
knockout mice (Figure 11). 
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Figure 9. 14-3-3ζ knockout mice had defect in lung development. Hemotoxylin 
and Eosin staining was performed on lung tissue dissected from 18.5dpc 
embryos. The wild type lungs were inflated and had saccular structure. The 14-
3-3ζ knockout lungs were deflated, lack saccular structure and had thickened 
septae, increased mesenchymal compartment and more blood cells spread in 
the lung tissues. Scale bar indicates 50um in length 
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Figure 10. 14-3-3ζ did not affect proliferation and pneumocytes differentiation. 
Immunohistochemical staining of proliferation marker Ki67, type I pneumocyte 
marker SP-A and the type II pneumocyte marker AQP5 were performed on lung 
tissue sections from wild type (+/+) and 14-3-3ζ homozygous mutant (-/-) 
18.5dpc embryos. Scale bar indicates 200um in length. 
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Figure 11. Loss of 14-3-3ζ lead to angiogenesis defect in lungs. Blood vessel 
endothelial cell marker CD-34 was stained immunohistochemically on 18.5dpc 
embryos lungs. 14-3-3ζ knockout lungs had leaky bid blood vessels and fewer 
peripheral blood vessels. Aggregation of leukocytes was present around the 
broken vessels in 14-3-3ζ knockout lungs. Scale bar indicates 200um in length.  
 
 
 
CD34 
+/+  
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42 
3.2c microRNA-126 is downregulated in 14-3-3ζ knockout lungs 
 To understand the key molecular mechanism mediating respiratory 
distress, I searched the Mouse Genome Infomatics (MGI) database on the 
Jackson Laboratory using key word “lethal”, “respiratory” and “angiogenesis”. 
More than 100 genes popped out, among which a lot are 14-3-3ζ binding 
proteins like TgfβRI, β-catenin. Interestingly, microRNA-126 is the only 
microRNA in the list.  
MiR-126 is an endothelial specific microRNA that regulates vascular integrity 
and angiogenesis (76-78).Targeted deletion of miR-126 resulted in lethality and 
lung deflation due to vascular abnormalities. The angiogenic signaling was 
significantly diminished in the knockout tissues and resulted in defective 
endothelial sprouting, adhesion and growth (76). MiR-126 was upregulated by ~ 
3 fold in our 14-3-3ζ overexpression cell line compared to the vector control cell 
line as determined by a microRNA microarray. 
I extracted RNA from the lung tissue and performed real-time quantitative 
reverse-transcript polymerase-chain reaction (qRT-PCR) and found that the 
miR-126 level was significantly downregulated in the 14-3-3ζ knockout lungs 
comparing to the wild type counterparts (Figure 12).  
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Figure 12. MicroRNA-126 was downregulated in 14-3-3ζ knockout lungs. Total 
RNA was extracted from 18.5dpc lung tissues from wild type (+/+) and 14-3-3ζ 
knockout (-/-) embryos. MiR-126 expression level was determined by 
quantitative real-time RT-PCR normalized to PECAM1 mRNA level.  
  
* 
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3.2d Discussion 
Here I observed the neonatal lethality in 14-3-3ζ knockout mouse under C57Bl/6 
genetic background.  
Genetic background apparently play important role mediating this phenotype, as 
several 14-3-3ζ knockout mice survived at the time of genotyping which is 10 
days after birth. Combining with the data later in part 3.3, the knockout mice are 
completely viable and fertile in CD-1 and FVB/N genetic background. One 
possible reason may be that different strains have different alternative splicing 
capability. The 14-3-3ζ expression level may be much lower in the B6 genetic 
background. My data did not support this view. The expression level of 14-3-3ζ 
remained low in all the genetic background. This leads to another possible 
explanation that 1 or more C57Bl/6 specific mutations in addition to loss of 14-3-
3ζ resulted in the lethality. It will be interesting to study which genes they are. If 
someone is to develop 14-3-3z targeting therapy for patients, it is important to 
identify and exclude those patients bearing such mutation from the therapy to 
prevent severe side effects. 
MiR-126 downregulation correlated with the 14-3-3ζ loss mediated lethality. 
However, miR-126 was only downregualted about half in 14-3-3ζ knockout mice 
lungs. MiR-126 heterozygous mutant mice were viable and fertile. Also 14-3-3ζ 
knockout mouse did not completely phenocopy the miR-126 knockout mouse. 
So downregulation of miR-126 is not the only mechanism underlying the 
respiratory failure phenotype mediated with defective angiogenesis. MiR-126 
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downregulation in addition to global signaling deregulation finally lead to this 
phenotype. Many other molecules like those mediating TGF-β signaling, 
Ras/Raf/Erk and PI3K/Akt signaling could also mediate this phenotype. I 
recently found that loss of 14-3-3ζ resulted in reduced HIF1-α, a well known 
oncogene that promotes angiogenesis by transcriptionally activate VEGF in 
multiple tissue types. It will be interesting to further study the how loss of 14-3-3ζ 
lead to neonatal lethality. Measuring the HIF1-α expression in the embryo lungs 
may help us gain more function.  
It will also be interesting to study whether miR-126 downregulation is playing a 
causal role in the lethality phenotype. I can either cross the 14-3-3z knockout 
mouse to miR-126 transgenic mouse and test whether ectopically expressing 
miR-126 could rescue the phenotype. 
MicroRNAs are able to target multiple mRNAs to regulate cellular processes. 
Many miR-126 targets have been reported to date. Spred-1 which is a 
suppressor of Ras/Raf/Erk signaling in response to VEGF stimulation is inhibited 
by miR-126 (76). VCAM1, which is a cell surface adhesion molecule, was 
upregulated in response to TNF-α stimulation when miR-126 is knocked down. 
Overexpression of VCAM1 resulted in more leukocyte adhesion to endothelial 
cells (91). This data matched my observation that more leukocytes are visible in 
the 14-3-3ζ knockout embryo lungs especially around the blood vessels. In the 
future, it will be interesting to determine the expression level of the miR-126 
targeting genes and test how important miR-126 is in this lethality phenotype. 
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3.3 Loss of 14-3-3ζ inhibited mammary gland tumor formation and lung 
metastasis 
3.3a Outbreeding rescues the lethality 
 The lethality hindered our study of 14-3-3ζ role in adulthood diseases like 
cancer. As we found a proportion of homozygous mutant pups could survive the 
lethality in B6/129P2 hybrid genetic background, it is likely that outbreeding may 
circumvent the lethality phenotype. To test this, I outbred the 14-3-3ζ knockout 
strain to CD-1. Approximately 25% of homozygous mutant pups were generated 
by mating heterozygous males and females after outbreeding (table 1), which 
indicated that the outbreeding rescued the neonatal lethality. The 14-3-3ζ 
knockout mice could also breed without any obvious defect. At the same time, I 
also backcrossed the strain to FVB/N congenic background. The 14-3-3ζ 
knockout mice under FVB/N genetic background were also viable and fertile.  
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3.3b Loss of 14-3-3ζ did not significantly affect mammary gland 
development 
 In our initial attempt to study the role of 14-3-3ζ in breast cancer, we first 
examined the mammary gland development in 14-3-3ζ knockout mice. 
Mammary glands were dissected from the mice at 4, 6, 8 and 12 weeks of age 
by biopsy. We performed whole mount staining of the mammary gland and 
found that the mammary gland parenchyma outgrowth was slightly delayed at 4 
and 6 weeks of age in the knockout mice. The epithelial parenchyma in the wild 
type mammary gland exceeded the lymph node in contrast to that in the 14-3-3ζ 
knockout mice barely touched the lymph node at 4 week of age. At the age of 8 
weeks, the outgrowth of the duct was restored to that in the wild type mice 
(Figure 13). The 14-3-3ζ knockout female mice could breed and nurse the pups, 
which also suggested that the 14-3-3ζ knockout mammary glands were 
biologically functional. 
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Figure 13. Loss of 14-3-3ζ did not significantly affect mammary gland 
development. The fourth mammary glands from the left side of the mice were 
dissected at the time points of 4, 6, 8 and week of age as indicated. Whole 
mount staining was performed to determine the epithelial parenchyma outgrowth 
and branching. Scale bar indicates 5mm in length. 
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3.3c Loss of 14-3-3ζ inhibited mammary gland tumor formation and 
metastasis induced by PyMT 
 To study the role of 14-3-3ζ in breast cancer, we crossed the 14-3-3ζ 
knockout mouse strain with MMTV promoter driven Polyoma middle T antigen 
(PyMT) transgenic strain which develops mammary gland tumor at an early age. 
The 14-3-3ζ knockout mice had significantly longer latency of tumor onset. The 
mice were sacrificed when the tumor diameter reached 15 mm. The tumors were 
harvested for further study. Histological study of the tumor suggested that loss of 
14-3-3z did not affect the tumor subtype. The tumors from both wild type and 14-
3-3z knockout mice are invasive adenocarcinomas. The lungs were dissected to 
determine the number of lung metastases by visually counting the surface tumor 
nodules. The 14-3-3ζ knockout mice had significantly lower number of lung 
metastases nodules (Figure 14).  
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Figure 14. Loss of 14-3-3ζ inhibited tumorigenesis and lung metastasis. A. 14-3-
3ζ homozygous mutant mice (-/-, n=8) had significantly longer tumor latency 
induced by PyMT compared to the wild type (+/+, n=10) and heterozygous 
mutant (+/-, n=17) counterparts. B. 14-3-3ζ homozygous mutant mice had 
reduced lung metastasis as determined by surface tumor nodule number. *** 
indicates P value < 0.0001.  
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3.3d 14-3-3ζ knockout tumors express lower 14-3-3ζ level 
Because the gene trap inactivates the expression of 14-3-3ζ by utilizing the 
transcription splicing machinery, it is possible that the tumors in the knockout 
mice may arise from single cells that express comparable level of 14-3-3ζ as 
that in wild type cells. We performed both western blot (Figure 17) and 
immunohistochemical staining on the tumors (Figure 15). We found that the 
tumors from the knockout mice expressed much lower level of 14-3-3ζ 
compared to the tumors araised from the 14-3-3ζ wild type mice. This suggested 
that the tumors from the knockout mice did not arise from cancer initiating cells 
expressing high level of 14-3-3ζ . This data also suggested that knockdown of 
14-3-3ζ was not sufficient to completely inhibit PyMT oncogene induced tumor 
formation. To cure cancer expressing high level of 14-3-3ζ need combination of 
other therapy regimen with 14-3-3ζ target therapy. 
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Figure 15. 14-3-3ζ expression is downregulated in the tumors from homozygous 
mutant mice. A. Immunohistochemical staining of 14-3-3ζ was performed on 
tumor tissues from the mice. B. Quantification was performed using the IRS 
scoring system from 0-3 with 0 indicating no expression and 3 indicating the 
highest expression of 14-3-3ζ. 14-3-3ζ expression was significantly lower in the 
knockout tumors. 
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3.3e Loss of 14-3-3ζ affected multiple aspects in tumor biology by 
regulating multiple signaling pathways 
Next I studied how loss of 14-3-3ζ resulted in inhibited tumor formation and 
metastasis. By staining the tumor slides with proliferation marker Ki67, apoptosis 
marker TUNEL, and angiogenesis marker CD34, I found that the 14-3-3ζ 
knockout tumors had reduced proliferation, increased apoptosis and reduced 
angiogenesis compared to their wild type counterparts (Figure 16). 
To study the molecular mechanism underlying these biological changes in the 
14-3-3ζ knockout tumors, I started with a reverse phase protein array (RPPA) 
assay performed in the Functional Proteomics Reverse Phase Protein Array 
Facility at MD Anderson Cancer Center, which contained about 135 antibodies 
to determine what molecules were deregulated in 14-3-3ζ knockout tumors. Two 
signaling pathways could be activated downstream of PyMT and those are the 
Ras/Raf/Erk and PI3K/Akt signaling pathways. , Both the signaling pathways 
were significantly inhibited in the knockout tumors as indicated by phospho-Raf-
S388, phospho-Mek1-S217, phospho-Akt-T308 and phospho-Akt-S473 (Figure 
17A).This finding was further validated by western blot. I found that phospho-
Erk1/2-T202/Y204 and phospho-Akt-S473 was downregulated in the knockout 
tumors indicating the Ras/Raf/Erk and PI3K/Akt signaling pathways were 
inhibited in knockout tumors. I also found that the well known tumor suppressor 
p53 was upregulated in the knockout tumors. These data matched the previous 
reports that 14-3-3ζ overexpression activated Akt and hence suppressed p53 via 
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phosphorylation-dependant activation of Mdm2 (69). Two molecules 
downstream of p53, the pro-apoptotic protein Bax which is transcriptionally 
activated by p53 was upregulated, whereas the pro-angiogenic protein VEGF 
transcriptionally suppressed by p53 was significantly downregulated. These data 
at least partially explained the reduced proliferation, angiogenesis and increased 
apoptosis as observed in knockout tumors (Figure 17B).  
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Figure 16. Loss of 14-3-3ζ affected multiple aspects of cancer biology. A. 
Proliferation marker Ki67 was immunohistochemically staining in the tumor 
samples and quantified. Ki67 index indicates the percentage of Ki67 positive 
cells in 10 randomly selected fields. Scale bar indicates 50um in length. B. 
Immunohistochemical staining of apoptosis marker Tunel and quantification. 
Tunel index indicates the Tunel positive cells in 10 randomly selected high 
power fields. Scale bar indicates 200um in length. C. immunohistochemical 
staining of angiogenesis marker CD34 and quantification. CD34+ index indicates 
blood vessel numbers in 10 randomly selected fields. Scale bar indicates 
100umin length. Quantification data are presented as mean ± standard error or 
the mean. ** indicates P-value <0.01, *** indicate P-value<0.0001.  
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Figure 17. Loss of 14-3-3ζ affected multiple signaling molecules expression. A. 
Heat map of reverse phase protein array results comparing the gene expression 
profiles in wild type and 14-3-3ζ homozygous mutant tumors. Clustering was 
calculated using software Cluster 3.0 and the heat map was generated using 
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JAVA tree. B. Western blot results confirmed that inactivation of Ras/Raf/Erk 
and PI3K/Akt in the 14-3-3ζ knockout tumors as determined by p-Erk and p-Akt. 
Total Erk and Akt were blotted as control and β-actin was used as loading 
control. 14-3-3ζ was blotted to confirm that 14-3-3ζ expression was inhibited in 
the 14-3-3ζ homozygous mutant tumors. 
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3.3f loss of 14-3-3ζ inhibited tumorigenesis induced by Neu oncogene 
Interestingly, we also found that PyMT expression level was also reduced 14-3-
3ζ knockout tumors (Figure 17). PyMT could bind to 14-3-3ζ when 
phosphorylated on serine 257(23). S257 mutated PyMT inhibited salivary gland 
tumor formation compared to wild type viral antigen (92).  To rule out the 
possibility that the inhibited tumor formation and metastasis was due to 
downregulated expression of PyMT mediated by loss of 14-3-3ζ, we crossed the 
14-3-3ζ knockout strain with MMTV driven activated Neu (NDL 2-5) transgenic 
mouse strain. The 14-3-3ζ knockout mice also exhibited delayed tumor onset 
induced by Neu (Figure 18), whereas the expression level of ErbB2 was not 
downregulated as determined by western blot (Figure 19). Immunohistochemical 
analysis confirmed that the 14-3-3ζ knockout lead to reduced proliferation, 
angiogenesis and increased apoptosis (Figure 20). These data suggested that 
inhibition of tumor formation and metastasis is not due to downregulation of 
PyMT in the 14-3-3ζ knockout mice but to the loss of 14-3-3ζ mediated global 
signaling deregulation. So loss of 14-3-3ζ could inhibit tumor formation in two 
different tumor prone mouse models.  
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Figure 18. Loss of 14-3-3ζ prolonged tumor latency induced neu oncogene. 
Kaplan-Meyer curve study of the percentage of tumor free mice along with the 
age of the neu transgenic mice is diagramed. P-value is indicated as shown. 
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Figure 19. Neu oncogene expression was not affected in 14-3-3ζ knockout 
tumors. Western blot of Neu in 14-3-3ζ wild type and homozygous mutant 
tumors induced by neu oncogene. GAPDH was used as loading control. 
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Figure 20. Loss of 14-3-3ζ affects tumor biology in Neu oncogene induced 
tumors. A. Immunohistochemical staining of proliferation marker Ki67 and 
quantification. Ki67 index was calculated as percentage of Ki67 positive cells in 
10 randomly selected fields. B. Immunohistochemical staining of apoptosis 
marker caspase 3 and quantification as average caspase 3 positive cell 
numbers every high power field (hpf) from 10 randomly selected fields. C. 
Immunohistochemical staining of angiogenesis marker CD34 and quanfication. 
CD34+ index indicates the average blood vessel number per hpf from 10 
randomly selected fields. Scale bar indicates 200um in length. Quantification 
data presented as mean± standard error of the mean. * indicates P-value<0.05, 
** indicates P-value<0.01 and *** indicates P-value<0.001. 
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3.3g miR-126 is downregulated in 14-3-3ζ knockout tumors 
 I previously found that microRNA-126 was along with defective 
angiogenesis downregulated in 14-3-3ζ knockout lung tissues. Angiogenesis 
was also reduced in 14-3-3ζ knockout tumors. In my initial test whether miR-126 
was also an important mediator of defective angiogenesis induced by loss of 14-
3-3ζ in tumors, I used quantitative real-time RT-PCR to measure miR-126 
expression level in the tumor samples and found that miR-126 was significantly 
downregulated in 14-3-3ζ knockout tumors (Figure 21).  
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Figure 21. MicroRNA-126 was downregulated in 14-3-3ζ knockout tumors. Total 
RNA was extracted from wild type and 14-3-3ζ knockout tumor tissues induced 
by PyMT. qRT-PCR of miR-126 was perfomed and normalized to 
PECAM1/CD31.Fold change of miR-126/CD31 ratio is presented as mean ± 
standard error of the mean. ** indicates P-value < 0.01. 
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3.3h miR-126 regulates angiogenesis downstream of 14-3-3ζ 
 To further test whether miR-126 was one of the key players in the 
angiogenesis defect mediated by loss of 14-3-3ζ. First of all, I transfected the 
mouse endothelial cell line with scramble or 14-3-3ζ shRNA and found that 
knocking down 14-3-3ζ significantly inhibited the angiogenic capability of the 
mouse endothelial cells as determined by transwell migration assay and tube 
formation assay (Figure 22). This in vitro result supported the in vivo finding that 
14-3-3ζ was critical in angiogenesis both in embryo lungs and tumors. When I 
transfected the 14-3-3ζ knockout down cells with pre-miR-126, the angiogenic 
capability was restored (Figure 22). These data suggested that miR-126 was a 
key regulator of angiogenesis downstream of 14-3-3ζ. 
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Figure 22. microRNA-126 regulates angiogenesis downstream of 14-3-3ζ. A. 
Mouse endothelial cells were transfected with scramble or 2 independent 14-3-
3ζ shRNAs. 14-3-3ζ knockdown efficiency was determined by western blot. β-
actin was used as loading control. B. Image of the transwell migration assay and 
quantification. Cells transfected with scamble or 14-3-3ζ shRNA in combination 
with control pre-microRNA or pre-miR-126 were tested for the migration 
capability. Migrated cells were stained with crystal violet, imaged and quantified 
with ImageJ. Data presented as mean ± standard error of the mean. C. Image of 
the tube formation assay and quantification. The cells were seeded on matrigel 
and cultured in incubator for 4-12 hours and imaged. Tube formation capability 
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was determined by the average length of the tube structure formed every high 
power field. Assays were repeated 3 times. Data presented as mean ± standard 
error of the mean. 
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3.3i Discussion 
 14-3-3ζ has been considered a potential oncogene and therapy target. 
Here we found that loss of 14-3-3ζ significantly inhibited tumorigenesis, 
progression and lung metastasis in two different tumor prone mouse models.  
 Hundreds of proteins have been reported to form complexes with 14-3-3ζ. 
It was not a surprising to see in the RPPA analysis that many genes expression 
are differential between the wild type and 14-3-3ζ knockout tumors. With the 
global signaling deregulation, I can easily explain the tumor biology change such 
as reduced proliferation, increased apoptosis and reduced angiogenesis in the 
14-3-3ζ knockout tumors. This inhibited tumorigenesis and lung metastasis 
suggested to me that 14-3-3ζ can be a potential therapy target. Though 
knocking down of 14-3-3ζ alone could not completely inhibit tumor formation or 
cure tumor, one can try treating the mice with chemo- or redioacitve therapeutic 
regimens and test the potential of combinational therapy. As in clinic many 
targeted therapies are used in combination with chemotherapy, it is possible that 
combinational therapy could cure the tumor. 
MicroRNA-126 has been shown to be downregulated in 14-3-3ζ knockout 
embryo lungs. Here miR-126 is also downregulated along with reduced 
angiogenesis in 14-3-3ζ knockout tumors suggesting miR-126 regulation by 14-
3-3ζ is a conserved signaling both in lung development and tumor progression. 
MiR-126 role in cancer remains controversial. Some published papers argue that 
miR-126 functions as a tumor suppressor in breast cancer (84, 93, 94). It was 
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hypothesized that downregulation of miR-126 could result in leaky blood vessel 
and thus enhancing metastasis. However, these studies were performed using 
epithelial cell lines or the whole tumor in which epithelial cells were the major 
compartment, whereas miR-126 expression was restricted in endothelial cells. 
So it would be reasonable to normalize the miR-126 expression level to 
endothelial specific housekeeping gene. As I mentioned, I used PECAM1 as 
control in this study. How miR-126 functions in cancer remains to be further 
studied. 
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3.4 14-3-3ζ knockout mice are growth retarded 
3.4a 14-3-3ζ knockout mice are smaller than their littermates 
 Interestingly, except the inhibited tumor formation and progression, I also 
observed that the 14-3-3ζ knockout mice are smaller than their wild type and 
heterozygous littermates after outbreeding (Figure 23). They weigh less than 
their wild type counterparts since 2 week of age. The difference got most 
significant at 3 and 4 week of age. Then the knockout mice could catch up to 
some extent later (Figure 23). Because the time matched the puberty onset in 
mice, this data suggested that the14-3-3ζ  knockout mice seemed to be smaller 
and have late onset of puberty and are growth retarded.  
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Figure 23. 14-3-3ζ  knockout mice are growth retarded. A. Image of the 14-3-3ζ  
wild type (wt), heterozygous (het) and homozygous mutant (homo) mice on the 
weaning date which is 3 week of age. Top panel image was taken on male mice 
in one litter and bottom panel was taken on female mice from one litter. B. 
Mouse weight along with the age. Weigh data gram (g) were obtained from 2 to 
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8 week (wk) of age from wild type and homozygous mutant mice presented as 
mean ± standard error of the mean. * indicates P-value<0.05, ** indicates P-
value<0.01 and *** indicates P-value<0.0001.  
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3.4b 14-3-3ζ knockout mice had reduced growth hormone but increased 
IGF-1 in circulation 
 As the most significant difference in weight between wild type and the 
knockout mice was observed at the age around 3-4 weeks which matched the 
puberty onset in mice, it suggested that 14-3-3ζ had impact on puberty onset in 
mouse. Growth hormone and insulin-like growth factors are well documented to 
regulate pubertal growth (95-98). I measured circulating growth hormone and 
IGF-1 to start with. Interestingly, compared to the reduced growth hormone level 
in the knockout mice circulation as I expected, the serum IGF-1 level was 
significantly increased in the knockout mice blood (Figure 24).  
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Figure 24. Loss of 14-3-3ζ lead to aberrance in growth related hormonal 
expression. A. Serum samples were drawn from 4 week old mice tail vein. 
Growth hormone level was measure using ELISA following standard protocol. B. 
Active IGF-1 level was measured using RIA kit following the product instruction. 
Sample size of each group was indicated in the figure. ** indicates P-value<0.01 
and *** indicates P-value< 0.0001.  
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3.4c 14-3-3ζ knockout mice had aberrant glucose homeostasis 
 As I observed the increased IGF-1 in the 14-3-3ζ knockout mouse 
circulation in contrast to our expectation, and IGF-1 and its receptors play critical 
role in regulating growth and glucose homeostasis, I tested whether there was 
any aberrance in glucose homeostasis in the 14-3-3ζ knockout mice. 
Interestingly, I found that the blood glucose level in the knockout mice was 
significantly lower than that of the wild type mice (Figure 25). As IGF-1 promotes 
glucose uptake and regulates glucose homeostasis (99, 100), this data matched 
the observation of increased IGF-1 level in the 14-3-3ζ knockout serum. 
However, interestingly, loss of 14-3-3ζ inhibited Akt activation observed in 
multiple studies including the tumorigenesis study induced by PyMT as 
previously described in this dissertation. Akt promotes glucose uptake by 
regulating multiple signaling pathways (101). Next I did glucose tolerance assay 
to better understand how 14-3-3ζ impacts glucose homeostasis. Remarkably, I 
found that though the basal blood glucose level was lower in the 14-3-3ζ 
knockout mice after 16 hour fasting, after glucose challenge, the glucose 
clearance from the blood was much slower in the knockout mice compared to 
the wild type counterparts. This data suggested that the glucose uptake was 
inhibited in the 14-3-3ζ knockout mouse tissues. To test this, I injected the mice 
with a fluorescent glucose homolog, 2-NBDG into the mice via i.v., harvested the 
brain and liver tissues which are the tissues uptake majority of glucose from 
circulation and measured the glucose uptake level indicated by 2-NBDG 
fluorescence intensity. I found the 2-NBDG level in the 14-3-3ζ knockout mice 
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brain and liver tissues was much lower than that in the wild type tissue (Figure 
26).  
 Based on these data, I conclude that 14-3-3ζ affected glucose 
homeostasis. 
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Figure 25. Loss of resulted in lower blood glucose. A drop of blood was drawn 
from mouse tail snip ad libitum. Blood glucose was measure using Roche 
AccuChek blood glucose meter. Sample size was indicated as shown. ** 
indicates P-value<0.01.  
** 
Figure 26. 14-3-3ζ regulates glucose uptake. A. 14
glucose tolerance. Age matched 14
mice were fasted 16 hours. 3g/kg weigh glucose was injected intraperitoneally. 
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Blood glucose was measured using blood retrieved from the tail snips at the time 
points indicated in the figure. * and *** indicated  that the blood glucose levels 
were statistically significantly different between the groups. (*, P<0.05; ***, 
P<0.001). B. Representative images of 2-NBDG fluorescent signal in 14-3-3ζ 
wild type and 14-3-3ζ knockout mouse brain visualized by the Maestro system. 
Fold change of 2-NBDG signal intensity quantified by Image J software. Data 
presented as mean ± standard error of the mean. * indicates statistical P-
value<0.05.  
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3.4d molecular mechanism underlying the defective glucose homeostasis 
 Then I wondered what was the molecular mechanism mediating the 
reduced glucose uptake. HIF1-α and IGF1R caught my attention. HIF1-
α, hypoxia induced factor 1 alpha, is a well known transcription factor that 
regulates glucose homeostasis, angiogenesis and cell survival by 
transcriptionally activate PGK1, LDH1, Glut1 and other hypoxia responsive 
genes like VEGF (102, 103). 14-3-3ζ overexpression activates Akt (69), which is 
also involved in reprogramming of metabolic genes.  Additionally, activation of 
mTOR, downstream of Akt, could lead to activation of HIF1-α that  could drive 
the major cancer metabolic changes (104).  IGF1R activates PI3K/Akt signaling 
pathway and can regulates glucose homeostasis (105). Loss of IGF1R resulted 
in neonatal lethality due to respiratory failure and severe dwarfism (106). I 
measured the expression level of HIF1-α in mouse mammary gland and IGF1R 
in mouse embryonic fibroblast (MEF) cells. I found that HIF1-α and IGF1R 
expression level was significantly downregulated in 14-3-3ζ knockouts (Figure 
27). So HIF1-α and IGF1R can be regulated by 14-3-3ζ to maintain glucose 
homeostasis. 
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Figure 27. 14-3-3ζ regulates HIF1-α and IGF1R. A. Loss of 14-3-3ζ 
downregualted HIF1-α. Protein lysates extracted from mammary glands of wild 
type (+/+) and knockout (-/-) mice. B. Loss of 14-3-3ζ downregulated IGF1R. 
Protein lysate extracted from immortalized mouse embryonic fibroblast (MEF) 
cells generated from wild type (+/+), heterozygous (+/-) and 14-3-3ζ 
homozygous knockout (-/-) mouse embryos.
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3.4e Discussion 
Growth hormone/Igf-1 axis signaling has been reported to regulated mammary 
gland development (107), animal stature(106) and glucose homeostasis (108). 
Growth hormone is secreted by the pituitary into the circulation and promotes 
IGF-1 expression in peripheral tissues, mainly in liver to promote cell growth 
(109). 
It is interesting that I found reduced cellular IGF1R and increased IGF-1in 
circulation. This data indicated that reduced receptor level rendered the tissues 
insensitive to the IGF-1 ligand. To maintain homeostasis, the tissues may 
express more ligand to keep the balance. This is typically true in growth retarded 
patients resistant toIGF-1 (110-113). This phenomenon is similar to type II 
diabetes in which the tissues are resistant to insulin. Pancreas β-cells had to 
express more insulin to keep normal glucose level after feeding. This will result 
in high blood glucose level along with high insulin. When the IGF-1 level was 
higher in 14-3-3ζ knockout mouse blood, a feedback signaling would make the 
pituitary express less growth hormone. This may explain the phenomenon such 
as delayed puberty onset and reduced blood glucose level I observed in the 
animal.  
Insulin, compared to IGF-1, is more efficient to promote glucose uptake but 
tightly regulated by blood glucose level, whereas IGF-1 regulates glucose 
homeostasis in a more consistent manner. IGF1R deletion also rendered the b-
islet cells secret lower insulin (114, 115). As to that the 14-3-3ζ knockout mice 
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also displayed better glucose tolerance, it would be interesting to further 
measure  the insulin level and β-cell function in the knockout mouse and study 
the differential role of insulin and IGF-1 in regulating glucose homeostasis. 
 GH/IGF-1 axis is also involved in puberty onset and mammary gland 
development. I also observed that the mammary gland development is slightly 
delayed in the 14-3-3ζ knockout mice matching the delayed puberty phenotype. 
Meanwhile, the IGF1R also plays important role in breast cancer formation and 
therapy resistance (116, 117). It is expected that IGF1R plays important role not 
only in the delayed puberty, mammary gland development and aberrant glucose 
homeostasis, but tumorigenesis and progression inhibition. Further study of how 
14-3-3ζ regulates IGF1R may provide insight of breast cancer formation 
progression and resistance to therapeutic regimens.  
 Recent studies suggest that metabolism plays important role in cancer 
(118-120). Our data strongly suggested that 14-3-3ζ plays important role in 
regulating metabolism likely through HIF1-α and IGF1R. Both of these genes 
regulate cancer progression (121, 122). More interestingly both the genes 
regulate angiogenesis (123-126). Many studies have suggested the important 
role of 14-3-3ζ in cancer. 14-3-3ζ can be a new bridge linking cancer and 
metabolism and provide new insight in cancer therapy. 
 I found that miR-126 was downregulated in 14-3-3ζ knockout embryos 
lungs and tumors. It is also reported that miR-126 was reduced in type II 
diabetes patients’ sera (79). Its role in diabetes is not clear yet. The 14-3-
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3ζ knockout mice may be resistant to insulin as indicated by better glucose 
tolerance. It will be interesting to further investigate whether miR-126 is playing 
some role mediating the energy deregulation caused by loss of 14-3-3ζ. Ptpn9 
which is a target of miR-126 is a phosphotase of EGFR and ErbB2 (127, 128). It 
has been reported to be involved in diabetes and cancer (129, 130). Currently I 
am studying its role in both cancer and glucose homeostasis. 
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3.5 Other phenotypes in 14-3-3ζ knockout mouse 
 The 14-3-3ζ knockout mice have other phenotypes to be further 
characterized. For example, the 14-3-3ζ knockout mouse did not spread out the 
rear limbs like the wild type mouse when lifted up via the tail, which suggested 
neuronal degeneration phenotype (Figure 28). As 14-3-3ζ has been reported to 
be involved in many human diseases as described in the introduction part of the 
thesis, it would be interesting to further study the function of 14-3-3ζ in those 
specific tissues.  
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Figure 28. 14-3-3ζ knockout mice display phenotype indicative of neuronal 
degenernation. The wild type mouse (left panel) spread the rear limbs outward 
when lifted up. The knockout mouse (right panel) clasped.  
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Chapter 4 Summary and Future Direction 
 In my thesis work, I generated a 14-3-3ζ hypomorphic mutant mouse 
strain. This animal model displayed multiple phenotypes under different genetic 
background such as neonatal lethality, delayed puberty, tumorigenesis inhibition 
and aberrant glucose homeostasis. I studied the function of 14-3-3ζ using this 
model and gained initial insight about the 14-3-3ζ role and the molecular 
mechanisms mediating these in vivo.  
I found different phenotypes in different genetic background. Loss of 14-3-3ζ 
resulted in neonatal lethality in C57Bl/6 genetic background due to respiratory 
failure. Loss of 14-3-3ζ inhibited tumorigenesis and progression in CD-1 and 
FVB/N genetic background. 14-3-3ζ mice are smaller and have delayed puberty 
onset in CD-1 strain. More phenotypes are to be characterized to study 14-3-3z 
in vivo function. 
 Using this model, we can better understand the role of 14-3-3ζ in human 
diseases like cancer. In the future, we may develop new target therapy related to 
14-3-3ζ to treat and benefit patients in clinic. 
 This strain is a whole body knockout mouse model. Now we know tissue 
microenvironment is critical for cellular function. A mouse model in which we can 
conditionally or induciblely manipulate the 14-3-3ζ could help us better 
understand the role of 14-3-3ζ in vivo. I designed a tetracycline inducible 14-3-
3ζ transgenic mouse strategy and this transgenic mouse strain has been 
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available in the lab now. We can generate more in depth insight of 14-3-3ζ 
function using this model in the near future. 
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